NRX Pharmaceuticals, Inc. insider trading
Every open-market purchase and sale by NRX Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following NRX Pharmaceuticals, Inc.’s insiders pay?
From March 17, 2020 to December 18, 2024, 10 insiders reported 11 open-market purchases and 6 sales not made under a pre-set plan in NRX Pharmaceuticals, Inc. After sales, the shares moved −13.7% against the index over 12 months (a negative figure means selling was the right call).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Javitt Jonathan C | Chairman and Chief Scientist | 4 | — | — | 1 | — | December 18, 2024 |
| Hurvitz Chaim | Director | 2 | — | — | 0 | — | September 11, 2023 |
| Javitt Daniel C. | 10% owner | 0 | — | — | 2 | — | August 2, 2022 |
| Van Voorhees Seth | CHIEF FINANCIAL OFFICER | 2 | — | — | 0 | — | December 19, 2022 |
| Besthof Robert | Chief Comm. & Patient Officer | 0 | — | — | 1 | −71.5% (1) | November 2, 2021 |
| Daigneault Alessandra | General Counsel & Secretary | 0 | — | — | 1 | −71.5% (1) | November 2, 2021 |
| Flynn Patrick John | Director | 1 | — | — | 0 | — | November 29, 2022 |
| Gorovitz Aaron | Director | 1 | — | — | 0 | — | September 11, 2023 |
| Polar Asset Management Partners Inc. | 10% owner | 0 | — | — | 1 | +101.9% (1) | March 17, 2020 |
| Willard Stephen H | CHIEF EXECUTIVE OFFICER | 1 | — | — | 0 | — | December 19, 2022 |